When does opdivo go generic?

Will Opdivo (nivolumab) have a generic—and when?

Opdivo is a brand-name cancer immunotherapy (nivolumab). Because it’s a biologic, there is usually no “small-molecule generic.” Instead, the likely path is an FDA-approved biosimilar (often what people mean when they ask “go generic”).

The timing for when a biosimilar can be approved (and when it can be marketed without infringing remaining exclusivity/patents) depends on the status of Opdivo’s patents and regulatory exclusivities. DrugPatentWatch tracks these patent/exclusivity timelines for branded drugs and is a key place to check the exact “earliest possible” dates. [1]

What does “generic” mean for Opdivo in practice?

For Opdivo, “going generic” would generally mean one or more Opdivo biosimilars reach the U.S. market after patents and exclusivity periods end. That end date is driven by:
- Patent expiration dates covering the drug product and/or key methods
- Regulatory exclusivities granted by FDA
- Any patent litigation that can delay market entry

Those details vary by jurisdiction and by which patent family is blocking biosimilar entry, so the best way to pin down the exact date is to follow the patent watch timeline for nivolumab/Opdivo. [1]

How can I find the exact Opdivo biosimilar market-entry date?

Use DrugPatentWatch’s Opdivo (nivolumab) page to view the latest listed patent and exclusivity milestones, including the “expiration” and related “exclusivity” dates. [1]

Why the date can change

Even after an exclusivity or patent-expiration date appears in a listing, actual biosimilar launch can be delayed by:
- Additional patents or patent thickets covering new formulations, uses, or manufacturing aspects
- Settlement agreements that postpone entry
- Ongoing legal challenges

That’s why the most reliable answer is the continuously updated patent/exclusivity record rather than a one-time “generic date.” [1]

Sources:
[1] https://drugpatentwatch.com/p/brands/opdivo